-
Je něco špatně v tomto záznamu ?
Similar Microvascular Inflammation and Tubulointerstitial Injury in ABO-Incompatible and Matched ABO-Compatible Kidney Allografts
K. Osickova, A. Parikova, J. Maluskova, J. Fronek, O. Viklicky,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články
Grantová podpora
NV15-26865A
MZ0
CEP - Centrální evidence projektů
- MeSH
- ABO systém krevních skupin imunologie MeSH
- alografty imunologie zásobování a distribuce MeSH
- biopsie MeSH
- desenzibilizace imunologická MeSH
- dospělí MeSH
- histokompatibilita imunologie MeSH
- hodnoty glomerulární filtrace MeSH
- ledviny krevní zásobení imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikrocévy MeSH
- nekompatibilita krevních skupin komplikace imunologie MeSH
- rejekce štěpu imunologie MeSH
- transplantace ledvin metody MeSH
- vaskulitida imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
ABO-incompatible (ABOi) kidney transplantation represents a viable tool to increase the donor pool for kidney transplantation, however, increased alloimmune response has been debated. The early outcomes of 25 low-risk ABOi kidney transplant recipients were compared with thoroughly matched 50 ABO-compatible (ABOc) ones. The matching process was based on gender and age of recipients and immunologic parameters, such as panel reactive antibodies, number of human leukocyte antigen mismatches, and transplantation era. Three-month protocol kidney graft biopsy Banff scores and 1-year clinical outcomes were compared. Apart from C4d positivity, no statistically significant differences were found regarding the Banff scores between the two groups. Similarly, microvascular inflammation and tubulointerstitial injury revealed no differences either. The eGFR at 3 months and 1 year was similar in both groups. In conclusion, blood group incompatibility yields no additional microvascular and tubulointerstitial graft injury if desensitization protocol was applied to low-risk kidney transplant recipients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000666
- 003
- CZ-PrNML
- 005
- 20201016161905.0
- 007
- ta
- 008
- 190107s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.transproceed.2018.02.063 $2 doi
- 035 __
- $a (PubMed)29880350
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Osickova, K $u Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 245 10
- $a Similar Microvascular Inflammation and Tubulointerstitial Injury in ABO-Incompatible and Matched ABO-Compatible Kidney Allografts / $c K. Osickova, A. Parikova, J. Maluskova, J. Fronek, O. Viklicky,
- 520 9_
- $a ABO-incompatible (ABOi) kidney transplantation represents a viable tool to increase the donor pool for kidney transplantation, however, increased alloimmune response has been debated. The early outcomes of 25 low-risk ABOi kidney transplant recipients were compared with thoroughly matched 50 ABO-compatible (ABOc) ones. The matching process was based on gender and age of recipients and immunologic parameters, such as panel reactive antibodies, number of human leukocyte antigen mismatches, and transplantation era. Three-month protocol kidney graft biopsy Banff scores and 1-year clinical outcomes were compared. Apart from C4d positivity, no statistically significant differences were found regarding the Banff scores between the two groups. Similarly, microvascular inflammation and tubulointerstitial injury revealed no differences either. The eGFR at 3 months and 1 year was similar in both groups. In conclusion, blood group incompatibility yields no additional microvascular and tubulointerstitial graft injury if desensitization protocol was applied to low-risk kidney transplant recipients.
- 650 _2
- $a ABO systém krevních skupin $x imunologie $7 D000017
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a alografty $x imunologie $x zásobování a distribuce $7 D064591
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a nekompatibilita krevních skupin $x komplikace $x imunologie $7 D001787
- 650 _2
- $a desenzibilizace imunologická $7 D003888
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hodnoty glomerulární filtrace $7 D005919
- 650 _2
- $a rejekce štěpu $x imunologie $7 D006084
- 650 _2
- $a histokompatibilita $x imunologie $7 D006648
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $x krevní zásobení $x imunologie $7 D007668
- 650 _2
- $a transplantace ledvin $x metody $7 D016030
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikrocévy $7 D055806
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a vaskulitida $x imunologie $7 D014657
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Parikova, A $u Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Maluskova, J $u Department of Clinical and Transplant Pathology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Fronek, J $u Department of Transplant Surgery, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Viklicky, O $u Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: ondrej.viklicky@ikem.cz.
- 773 0_
- $w MED00004556 $t Transplantation proceedings $x 1873-2623 $g Roč. 50, č. 5 (2018), s. 1305-1309
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29880350 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20201016161903 $b ABA008
- 999 __
- $a ok $b bmc $g 1363892 $s 1038789
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 50 $c 5 $d 1305-1309 $i 1873-2623 $m Transplantation proceedings $n Transplant Proc $x MED00004556
- GRA __
- $a NV15-26865A $p MZ0
- LZP __
- $a Pubmed-20190107